Skip to content
Biodatica
Start free

Janssen Research & Development, LLC

Neuss, California

Phase IIIListed · JNJ

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Sign in to watch

What changed

Phase III trial registered: Nipocalimab in Moderate to Severe Sjogren's Disease

1w agoTrial registeredJul 6, 2026Source filing (opens the source filing in a new tab)

Momentum

69no change

Momentum 69 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Dec 4, 2024

    Sjogrens Syndrome · ACTIVE_NOT_RECRUITING · sponsor: Janssen Research & Development, LLC · Nipocalimab in Moderate to Severe Sjogren's Disease

    ClinicalTrials.gov · NCT06741969 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Sep 17, 2019

    Major Depressive Disorder With Anxious Distress · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of JNJ-61393215 in the Treatment of Depression

    ClinicalTrials.gov · NCT04080752 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Jul 12, 2016

    Diabetes Mellitus, Type 2 · TERMINATED · sponsor: Janssen Research & Development, LLC · Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)

    ClinicalTrials.gov · NCT02862431 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources